BioXcel Therapeutics Profit Margin

The latest profit margin for BTAI is -11078.53% as of March 2026. That compares with -2163.17% in the prior-year period — down 412.1% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside BioXcel Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BTAI's profit margin moved from -2163.17% to -11078.53% — a 412.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioXcel Therapeutics's valuation or profitability profile.

Against Healthcare companies, BTAI currently prints -11078.53% for profit margin, while the sector average sits near 14.34%. That is roughly 77330.4% below the sector mean. Large gaps often invite a closer look at BioXcel Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively BioXcel Therapeutics converts resources into returns. At -11078.53%, BTAI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2163.17% in the prior-year period — down 412.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BTAI's profit margin (-11078.53%), review year-over-year change from -2163.17%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.